Verve Therapeutics Performance
| VERVDelisted Stock | USD 11.13 0.00 0.00% |
The entity has a beta of 0.21, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Verve Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Verve Therapeutics is expected to be smaller as well. Verve Therapeutics right now has a risk of 0.0%. Please validate Verve Therapeutics sortino ratio, semi variance, as well as the relationship between the Semi Variance and day typical price , to decide if Verve Therapeutics will be following its existing price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Verve Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Verve Therapeutics is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
| Begin Period Cash Flow | 211 M | |
| Total Cashflows From Investing Activities | 74.9 M |
Verve |
Verve Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,113 in Verve Therapeutics on October 26, 2025 and sell it today you would earn a total of 0.00 from holding Verve Therapeutics or generate 0.0% return on investment over 90 days. Verve Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Verve, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Verve Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Verve Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Verve Therapeutics, and traders can use it to determine the average amount a Verve Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Based on monthly moving average Verve Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Verve Therapeutics by adding Verve Therapeutics to a well-diversified portfolio.
Verve Therapeutics Fundamentals Growth
Verve Stock prices reflect investors' perceptions of the future prospects and financial health of Verve Therapeutics, and Verve Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Verve Stock performance.
| Return On Equity | -0.34 | |||
| Return On Asset | -0.19 | |||
| Operating Margin | (1.11) % | |||
| Current Valuation | 565.6 M | |||
| Shares Outstanding | 89.31 M | |||
| Price To Earning | 5.45 X | |||
| Price To Book | 2.10 X | |||
| Price To Sales | 16.68 X | |||
| Revenue | 32.33 M | |||
| EBITDA | (221.91 M) | |||
| Cash And Equivalents | 293.56 M | |||
| Cash Per Share | 4.90 X | |||
| Total Debt | 69.98 M | |||
| Debt To Equity | 0 % | |||
| Book Value Per Share | 5.33 X | |||
| Cash Flow From Operations | (157.69 M) | |||
| Earnings Per Share | (2.11) X | |||
| Total Asset | 647.39 M | |||
| Retained Earnings | (743.01 M) | |||
About Verve Therapeutics Performance
Evaluating Verve Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Verve Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Verve Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Verve Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 113 people.Things to note about Verve Therapeutics performance evaluation
Checking the ongoing alerts about Verve Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Verve Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Verve Therapeutics is not yet fully synchronised with the market data | |
| Verve Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 32.33 M. Net Loss for the year was (198.71 M) with loss before overhead, payroll, taxes, and interest of (150.82 M). | |
| Verve Therapeutics currently holds about 293.56 M in cash with (157.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.9. | |
| Over 95.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from globenewswire.com: INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of ETHZilla Corporation - ETHZ |
- Analyzing Verve Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Verve Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Verve Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Verve Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Verve Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Verve Therapeutics' stock. These opinions can provide insight into Verve Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Verve Stock
If you are still planning to invest in Verve Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Verve Therapeutics' history and understand the potential risks before investing.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |